CALA Surges On BMY Deal, OVAS Hands Pink Slips, MACK Halts Breast Cancer Study

Seeking to improve cost structure, OvaScience (OVAS) is reducing its workforce by approximately 30 percent and will slow the commercial expansion of its fertility treatment AUGMENT.

from RTT - Biotech http://ift.tt/2heVaR4
via IFTTT